Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors

BACKGROUND: Programmed cell death protein 1 (PD-1) pathway blockade with immune checkpoint inhibitors (ICIs) is a standard therapy in advanced hepatocellular carcinoma (HCC) nowadays. No strategies to overcome ICI resistance have been described. We aimed to evaluate the use of ipilimumab and anti-PD...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Jeffrey Sum Lung, Kwok, Gerry Gin Wai, Tang, Vikki, Li, Bryan Cho Wing, Leung, Roland, Chiu, Joanne, Ma, Ka Wing, She, Wong Hoi, Tsang, Josephine, Lo, Chung Mau, Cheung, Tan To, Yau, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7875295/
https://www.ncbi.nlm.nih.gov/pubmed/33563773
http://dx.doi.org/10.1136/jitc-2020-001945

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7875295/
https://www.ncbi.nlm.nih.gov/pubmed/33563773
http://dx.doi.org/10.1136/jitc-2020-001945

Ejemplares similares